Abstract
Background Atherosclerotic plaques are complex tissues composed of a heterogeneous mixture of cells. However, we have limited understanding of the comprehensive transcriptional and phenotypical landscape of the cells within these lesions.
Methods To characterize the landscape of human carotid atherosclerosis in greater detail, we combined cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) and single-cell RNA sequencing (scRNA-seq) to classify all cell types within lesions (n=21; 13 symptomatic) to achieve a comprehensive multimodal understanding of the cellular identities of atherosclerosis and their association with clinical pathophysiology.
Results We identified 25 distinct cell populations each having a unique multi-omic signature, including macrophages, T cells, NK cells, mast cells, B cells, plasma cells, neutrophils, dendritic cells, endothelial cells, fibroblasts, and smooth muscle cells (SMCs). Within the macrophage populations, we identified 2 proinflammatory subsets that were enriched in IL1B or C1Q expression, 2 distinct TREM2 positive foam cell subsets, one of which also expressed inflammatory genes, as well as subpopulations displaying a proliferative gene expression signature and one expressing SMC-specific genes and upregulation of fibrotic pathways. An in-depth characterization uncovered several subsets of SMCs and fibroblasts, including a SMC-derived foam cell. We localized this foamy SMC to the deep intima of coronary atherosclerotic lesions. Using CITE-seq data, we also developed the first flow cytometry panel, using cell surface proteins CD29, CD142, and CD90, to isolate SMC-derived cells from lesions. Last, we found that the proportion of efferocytotic macrophages, classically activated endothelial cells, contractile and modulated SMC-derived cell types were reduced, and inflammatory SMCs were enriched in plaques of clinically symptomatic vs. asymptomatic patients.
Conclusions Our multimodal atlas of cell populations within atherosclerosis provides novel insights into the diversity, phenotype, location, isolation, and clinical relevance of the unique cellular composition of human carotid atherosclerosis. This facilitates both the mapping of cardiovascular disease susceptibility loci to specific cell types as well as the identification of novel molecular and cellular therapeutic targets for treatment of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.C.B. is supported by the National Institute of Health Postdoctoral Training in Arteriosclerosis fellowship (5T32HL007343). M.L. is supported by National Institutes of Health grant Nos. R01GM125301, R01HL113147, R01HL150359, and R21HL156234. M.P.R. is supported for this work by National Institutes of Health grant Nos. R01HL113147, R01HL150359, and R01HL166916. A.C. is support by American Heart Association Predoctoral Fellowship 909206. R.C.B. is supported for this work by National Institutes of Health grant Nos. R01HL141745 and R01DK134026
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All human subjects research in this study, including the use of human tissues, conformed to the principles outlined in the Declaration of Helsinki. All patient information was de-identified. For single-cell studies, tissues from human carotid atherosclerotic plaques were collected from twenty-one patients undergoing carotid endarterectomy surgery. These human subject studies were performed with approval (protocol number AAAJ2765) of the local Institutional Review Board (IRB) of Columbia University Irving Medical Center, and written informed consent was obtained from all participants. Exclusion criteria include current infection, known immune system disorder, and active or recent (within last three months) radiation, chemotherapy, hormone-based, and/or immunotherapy treatment for cancer. For arterial immunohistochemistry, human coronary artery tissues were obtained from either donor hearts rejected for transplantation or explanted hearts during cardiac transplant surgery. These human subject studies were performed with approval (protocol number AAAR6796) of the local Institutional Review Board (IRB) of Columbia University. Written informed consent was obtained upon admission before surgery.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
De-identified single cell RNA sequencing, CITE-seq, clinical, and demographic datasets from the n=22 consented individuals described in this study (distributed among 21 carotid and 1 coronary artery specimens) will be deposited in NCBI GEO for public access at manuscript publication.
